Renal Cell Carcinoma

• VHL-HIF Pathway Dysfunction (Most Common in ccRCC): Loss of VHL (von Hippel-Lindau) tumor suppressor protein occurs in 80–90% of sporadic ccRCC through mutation, hypermethylation, or deletion. VHL normally functions to ubiquitinate and target hypoxia-inducible factors (HIF-1α and HIF-2α) for proteasomal degradation under normoxic conditions. When VHL is lost, HIFs accumulate regardless of oxygen tension, leading to constitutive activation of hypoxia-response elements (HREs). This drives transcription of vascular endothelial growth factor (VEGF), erythropoietin (EPO), platelet-derived growth factor (PDGF), and genes promoting angiogenesis and metabolic reprogramming. The resulting excessive tumor vascularity explains RCC's characteristic appearance on imaging and its responsiveness to anti-VEGF therapies. Additionally, HIF accumulation promotes metabolic shift toward glycolysis and lipid accumulation, contributing to the characteristic "clear cell" phenotype from triglyceride and cholesterol accumulation.

• MET Pathway Alterations (Papillary RCC): Papillary RCC frequently demonstrates activating mutations in MET (hepatocyte growth factor receptor) occurring in 10–40% of cases, particularly hereditary papillary RCC associated with MET germline mutations. MET activation triggers constitutive tyrosine kinase signaling through RAS/MAPK and PI3K/AKT pathways, promoting cell proliferation, survival, and invasion independent of growth factor stimulation. This mechanistic insight has led to development of MET-targeted therapies such as sunitinib and cabozantinib.

• BAP1 Loss and Chromophobe Pathogenesis: Chromophobe RCC typically arises from intercalated cells of the collecting duct and frequently features loss of BAP1 (BRCA1-associated protein 1), a deubiquitinase regulating DNA repair and cell cycle control. BAP1 loss impairs homologous recombination repair, leading to genomic instability and acquired mutations in TP53 and PTEN. These chromophobe tumors generally carry better prognosis than ccRCC but are more aggressive than oncocytomas.

• PBRM1, KDM5C, and Other ccRCC-Associated Alterations: Beyond VHL, approximately 40% of ccRCCs harbor mutations in PBRM1 (polybromo-1), a component of the SWI/SNF chromatin remodeling complex, impairing transcriptional regulation. KDM5C (also called JARID1C) mutations occur in 10–15% of ccRCC, affecting histone demethylation. TP53 mutations (present in 10–20% of ccRCC) correlate with high-grade disease and poor prognosis. These polygenomic alterations create a hypoxic, immunosuppressive microenvironment enriched in regulatory T cells and myeloid-derived suppressor cells, explaining RCC's partial resistance to immune checkpoint inhibition as monotherapy.

• Angiogenesis as a Core Pathogenic Feature: Beyond VHL-driven HIF/VEGF signaling, RCC tumors undergo extensive neovascularization mediated by multiple signaling pathways including VEGF, PDGF, and FGF. This angiogenic dependence creates a permissive environment for hematogenous dissemination and explains the efficacy of anti-angiogenic agents. Hypoxic regions within tumors, paradoxically, select for more aggressive clones with enhanced survival capabilities and metastatic potential.

• Chronic Kidney Disease and Dialysis-Associated RCC: Patients with chronic kidney disease, particularly those on long-term hemodialysis, demonstrate 10–30-fold increased RCC incidence. Acquired cystic kidney disease frequently develops in dialysis patients, with 1–5% progression to RCC. Proposed mechanisms include accumulation of nephrotoxic uremic waste products, chronic inflammation, impaired surveillance by reduced immune function, and potential effects of dialysate contaminants. This risk persists even after kidney transplantation, requiring surveillance in post-transplant patients.

• Smoking: Cigarette smoking increases RCC risk 1.5–2-fold, with dose-dependent relationship (>40 pack-years conferring higher risk). Tobacco smoke contains carcinogens including nitrosamines and polycyclic aromatic hydrocarbons that undergo metabolic activation in renal proximal tubule cells. Smoking cessation reduces but does not eliminate excess risk, reflecting earlier carcinogenic hits.

• Hypertension: Hypertension independently increases RCC risk approximately 1.5–2-fold, independent of diuretic use (earlier suspected as confounding factor). Mechanisms include chronic renal hypoperfusion, activation of renin-angiotensin system, and promotion of angiogenesis. Notably, antihypertensive therapy does not substantially reduce RCC incidence, suggesting the hypertension itself (rather than associated features) drives risk.

• Obesity: Elevated body mass index (BMI >30) increases RCC risk 1.5–2-fold in both sexes, with stronger association in women. Mechanisms include estrogen production in adipose tissue (relevant given hormonal factors in RCC pathogenesis), dysregulation of adipokines promoting inflammation and angiogenesis, and metabolic syndrome-associated insulin resistance. Weight reduction may reduce risk in prospective studies.

• Hereditary Syndromes: Multiple inherited cancer syndromes predispose to RCC through germline mutations:
• Von Hippel-Lindau (VHL) Syndrome: Autosomal dominant condition with VHL gene germline mutations causing 40–50% lifetime RCC risk, typically multifocal and bilateral, presenting in 4th-5th decade (earlier than sporadic disease). Affected individuals also develop hemangioblastomas, pheochromocytomas, and pancreatic neuroendocrine tumors.
• Hereditary Papillary RCC (HPRCC): Autosomal dominant MET mutations causing 100% RCC penetrance by age 80, typically papillary histology with generally favorable prognosis.
• Birt-Hogg-Dubé (BHD) Syndrome: Autosomal dominant FLCN gene mutations causing chromophobe and oncocytic RCC with 20–30% lifetime risk, often multifocal and bilateral.
• Hereditary Leiomyomatosis and RCC (HLRCC): Autosomal dominant fumarate hydratase (FH) deficiency causing aggressive papillary type 2 RCC with high metastatic potential.
• Familial Oncocytoma: Rare condition with multiple benign oncocytic tumors but rare malignant transformation.

• Estrogen/Hormone Replacement Therapy: Exogenous estrogen use in women increases RCC risk approximately 1.5-fold, supporting a role for estrogen signaling in RCC pathogenesis. This contrasts with protective effect of endogenous estrogen before menopause. Progestin exposure does not confer additional risk. Unopposed estrogen shows stronger association than combined estrogen-progestin preparations.

• Prior Malignancy: Previous history of lung, breast, or gastric cancer increases RCC risk, potentially through shared carcinogenic exposures (smoking, radiation), genetic predisposition, or therapy-related effects (prior chemotherapy or radiation).

• Medications: Chronic phenacetin use (now banned in most countries) increases RCC risk through nephrotoxic metabolites causing chronic interstitial nephritis. Nonsteroidal anti-inflammatory drug (NSAID) chronic use carries conflicting evidence but shows modest increased risk in some studies. Diuretics were historically suspected but large prospective studies do not support independent association.

• Hematuria (Cardinal Symptom): Gross or microscopic hematuria occurs in 40–60% of symptomatic patients, resulting from tumor invasion into collecting system or erosion through renal capsule into perirenal venous plexus. Hematuria may be painless and intermittent, leading to diagnostic delay. When present with other constitutional symptoms, hematuria strongly suggests RCC over benign causes (though most hematuria is benign). The mechanism involves both direct mucosal invasion and enhanced vascularity with friable surface.

• Flank Pain: Dull or sharp flank pain occurs in 20–40% of symptomatic patients, typically indicating larger tumors with invasion of renal capsule or perinephric tissues, or obstruction of urinary collecting system causing hydronephrosis. Pain character varies from aching discomfort to acute colicky pain if blood clots obstruct ureteral flow. Pain lateralizes to affected kidney and may radiate inferiorly toward groin.

• Palpable Flank Mass: Direct palpation of renal mass occurs in only 10–15% of patients, typically indicating advanced local disease. Mass detection requires substantial tumor size (usually >4 cm) and anterior location accessible to physical examination. This finding signals aggressive disease and often portends poorer prognosis due to later detection.

• Constitutional Symptoms (Paraneoplastic Syndrome): 10–20% of patients present with fever, unintentional weight loss, and fatigue without localizing symptoms, representing constitutional syndrome of malignancy. These symptoms result from IL-6 and TNF-α production by tumor and infiltrating immune cells. Constitutional symptoms correlate with advanced stage, high nuclear grade, and poor prognosis. Some patients demonstrate clinical improvement after nephrectomy despite lack of tumor reduction in other sites, suggesting systemic production of inflammatory cytokines by primary tumor.

• Polycythemia (Paraneoplastic): 5–10% of patients demonstrate erythrocytosis (hematocrit >50% or hemoglobin >16 g/dL in men, >14 g/dL in women) resulting from excessive erythropoietin (EPO) production by tumor cells or associated stromal cells. EPO hypersecretion occurs particularly in well-differentiated tumors and paradoxically indicates better prognosis than expected from stage alone. Elevated serum EPO levels (>100 mIU/mL) in setting of erythrocytosis confirm EPO-producing RCC. This paraneoplastic syndrome reverses after nephrectomy in most cases, distinguishing it from primary polycythemia.

• Hypercalcemia (Paraneoplastic): 5–10% of patients develop hypercalcemia through PTHrP (parathyroid hormone-related peptide) secretion or local osteolytic activity of bone metastases rather than ectopic calcitriol production (distinguishing from lymphomas). Hypercalcemia indicates advanced disease and poor prognosis. Manifestations include polyuria, polydipsia, neuropsychiatric changes (confusion, lethargy), and cardiac arrhythmias.

• Stauffer Syndrome: Non-metastatic hepatic dysfunction (elevated alkaline phosphatase, prolonged PT, hypoalbuminemia) occurs in 5–7% of patients without hepatic metastases, resulting from systemic inflammation and cytokine-mediated hepatocellular dysfunction. This syndrome reverses after successful nephrectomy, confirming its paraneoplastic nature.

• Hypertension: 20–40% of patients demonstrate elevated blood pressure, resulting from both underlying chronic kidney disease and tumor-related renin secretion by juxtaglomerular apparatus or ischemic renal parenchyma from mass effect. RCC-associated hypertension may be resistant to medical management and occasionally improves after nephrectomy if renin-dependent mechanism predominates.

• Varicocele (Left-sided): Acute onset left varicocele in adult (particularly age >40) may indicate left renal vein invasion by RCC with obstruction of testicular venous drainage. This finding should prompt imaging evaluation, though most varicoceles are benign idiopathic conditions. Right-sided varicocele is unusual and warrants investigation for infrarenal IVC obstruction.

• Lower Extremity Edema and Dilated Collateral Veins: These findings indicate venous invasion with IVC obstruction, typically occurring with large tumors at renal hilum. Edema may be acute or chronic, with collateral vessel development representing chronic venous obstruction.

• Atypical Presentations: RCC metastases may present as apparent primary malignancy in distant sites (bone metastasis as initial finding, lung nodule, brain metastasis), with occult primary RCC discovered on subsequent imaging. Patients may present with hemoptysis (lung metastasis), seizures or focal neurologic deficit (brain metastasis), or pathologic fracture (bone metastasis) before renal primary is identified.

• Urinalysis and Microscopy: Hematuria (≥3 RBCs per high-power field) detected on urinalysis or urine microscopy should prompt further evaluation, though lacks specificity (benign hematuria exceeds RCC-related hematuria by 40:1 ratio). Proteinuria or pyuria may coexist but lack diagnostic specificity. Urine cytology has poor sensitivity for RCC (15–20%) and is not recommended for diagnosis.

• Complete Blood Count: Baseline CBC documents hemoglobin/hematocrit (elevated in polycythemic patients), platelet count, and white blood cell count for prognostic assessment and baseline for future surveillance. Anemia (hemoglobin <10 g/dL) in RCC indicates advanced disease or prior bleeding. Thrombocytosis (platelets >400,000/μL) correlates with worse prognosis and aggressive disease.

• Comprehensive Metabolic Panel: Assess renal function (creatinine, BUN, GFR), electrolytes, and hepatic function (particularly alkaline phosphatase elevation suggesting Stauffer syndrome). Hypercalcemia (>10.5 mg/dL) indicates advanced disease and paraneoplastic syndrome. Elevated LDH suggests high-grade disease. Hypoalbuminemia correlates with systemic inflammation and poor prognosis.

• Serum Lactate Dehydrogenase (LDH): Elevated LDH (>400 IU/L) independently predicts aggressive disease, high nuclear grade, and poor prognosis; used in IMDC (International Metastatic RCC Database Consortium) prognostic model. LDH elevation reflects tumor burden and increased cellular turnover.

• Contrast-Enhanced CT Scan (Gold Standard for Diagnosis and Staging): Multiphasic CT with IV contrast (arterial, venous, and delayed phases) is imaging modality of choice for RCC detection and staging. Sensitivity for detecting masses >3 cm exceeds 95%, with lower sensitivity for masses <1 cm. RCC characteristically demonstrates:
• Arterial phase hyperenhancement: Tumor enhancement >20 Hounsfield units greater than renal cortex during arterial phase (30–40 seconds post-contrast) reflects tumor vascularity and angiogenesis
• Washout: Rapid washout in venous and delayed phases (enhancement decrease >30 HU from arterial peak

Immediate stabilisation (when relevant)

• Clot retention from gross hematuria: large-bore three-way catheter with continuous bladder irrigation; angioembolization of the renal artery for uncontrolled bleeding or in non-surgical candidates.
• Malignancy-associated hypercalcemia: isotonic saline volume repletion plus an antiresorptive (bisphosphonate such as zoledronic acid, or denosumab in renal impairment) — calcitonin bridges the first 48 hours.
• Metastatic spinal cord compression: emergency corticosteroid (dexamethasone), urgent whole-spine MRI, and neurosurgery/radiation oncology consultation.

Localized disease (AUA Guideline on Renal Mass and Localized Renal Cancer; NCCN Kidney Cancer)

• Partial nephrectomy: preferred nephron-sparing approach for cT1 masses, and mandatory for solitary kidney, bilateral tumors, CKD, or hereditary syndromes (VHL, BHD) where future tumors are expected.
• Radical nephrectomy: for large (cT2+), central, or locally advanced tumors; ipsilateral adrenalectomy only if the adrenal is involved. Renal vein/IVC tumor thrombus is resected with thrombectomy, sometimes on cardiopulmonary bypass.
• Thermal ablation (cryoablation, radiofrequency) or active surveillance: reasonable for small (<2 cm) masses in elderly or comorbid patients; percutaneous biopsy is advised before ablation or surveillance.
• Adjuvant immunotherapy: pembrolizumab (anti–PD-1) after resection of high-risk clear cell RCC is NCCN-endorsed; VEGF TKIs are not standard adjuvant therapy.

Advanced/metastatic disease (NCCN; ASCO metastatic RCC guideline), stratified by IMDC risk

• First line: doublet immunotherapy — ipilimumab (anti–CTLA-4) plus nivolumab for intermediate/poor risk, or an ICI plus VEGF tyrosine kinase inhibitor (pembrolizumab + axitinib, nivolumab + cabozantinib, pembrolizumab + lenvatinib).
• Later lines: single-agent VEGF TKI (cabozantinib), mTOR inhibitor (everolimus), or the HIF-2α inhibitor belzutifan, which directly targets the VHL–HIF axis and is also used for VHL syndrome–associated RCC.
• Cytoreductive nephrectomy is selective, not routine, since CARMENA showed sunitinib alone was non-inferior in poor-risk patients; metastasectomy or SBRT is used for oligometastatic disease.

Contraindicated/avoid

• Conventional cytotoxic chemotherapy: RCC is intrinsically chemoresistant (P-glycoprotein expression) — a classic wrong answer.
• VEGF TKIs perioperatively: impair wound healing; hold around surgery.
• Checkpoint inhibitors: avoid in active autoimmune disease or solid-organ transplant (rejection risk).

Disease-related

• IVC tumor thrombus: hematogenous growth up the renal vein into the IVC; signalled by new lower-extremity edema, dilated abdominal collaterals, or a non-reducing left varicocele. Propagation to the right atrium risks tumor pulmonary embolism — an emergency.
• Bone metastases: characteristically osteolytic and hypervascular, presenting with pathologic fracture or hypercalcemia; vertebral lesions causing back pain with myelopathy or bowel/bladder dysfunction indicate cord compression (emergency).
• Brain metastases: hypervascular and prone to hemorrhage; new seizure, focal deficit, or morning headache with vomiting suggests raised intracranial pressure (emergency).
• **Spontaneous perinephric hemorrhage (Wunderlich syndrome)**: rupture of friable neovasculature; flank pain, palpable mass, and hypotension.
• Post-nephrectomy CKD: reduced nephron mass with hyperfiltration injury in the remnant kidney; rising creatinine and new proteinuria.
• Paraneoplastic sequelae: EPO-driven erythrocytosis raises hyperviscosity/thrombosis risk; Stauffer syndrome cholestasis without liver metastases resolves after nephrectomy.

Treatment-related

• VEGF TKI toxicity (sunitinib, cabozantinib, axitinib): nitric-oxide depletion and rarefaction of the microvasculature cause hypertension (hypertensive emergency possible) and proteinuria; also hand-foot skin reaction, hypothyroidism, impaired wound healing, arterial thromboembolism, GI perforation, and posterior reversible encephalopathy syndrome (headache, seizures, cortical blindness — emergency).
• Immune-related adverse events (nivolumab, ipilimumab, pembrolizumab): loss of peripheral tolerance producing colitis (bloody diarrhea), pneumonitis (dyspnea with ground-glass opacities), hepatitis, thyroiditis, and hypophysitis. Myocarditis — troponin rise with conduction block — and adrenal crisis are emergencies. High-dose corticosteroids are the backbone of management, with checkpoint inhibitor withheld for grade ≥2 toxicity.
• mTOR inhibitor (everolimus): non-infectious pneumonitis, stomatitis, hyperglycemia, hypertriglyceridemia.
• Belzutifan (HIF-2α inhibitor): on-target suppression of erythropoietin causes anemia, plus hypoxia.

• Cell of origin and genetics: clear cell RCC arises from the proximal tubule and hinges on loss of VHL on chromosome 3p → unchecked HIF → VEGF/PDGF/EPO transcription. That single mechanism explains the hypervascular arterial-enhancing mass, the paraneoplastic polycythemia, and why anti-VEGF agents work.
• Best next step for a solid renal mass on ultrasound: multiphasic contrast-enhanced CT of abdomen and pelvis (with chest imaging for staging). A solid enhancing renal mass in a surgical candidate goes to resection — routine pre-op biopsy is not required, though biopsy precedes ablation or surveillance (AUA).
• Vascular spread is the signature: RCC invades the renal vein and IVC. Acute, non-reducing left-sided varicocele in an adult male = left renal vein obstruction until proven otherwise (the left gonadal vein drains into the left renal vein; the right drains directly into the IVC).
• The association examiners love: von Hippel–Lindau — bilateral, multifocal, early-onset clear cell RCC plus cerebellar/retinal hemangioblastomas and pheochromocytoma. Bilateral tumors in a young patient means think hereditary syndrome and nephron-sparing surgery.
• Paraneoplastic quartet: EPO → polycythemia (a hematocrit that is high rather than low), PTHrP → hypercalcemia, IL-6/TNF → fever and weight loss, and Stauffer syndrome (elevated alkaline phosphatase and transaminases with no liver metastases, reversible after nephrectomy).
• Metastatic pattern: lung (cannonball metastases), bone (osteolytic — the distractor is prostate cancer's osteoblastic lesions), liver, and brain. RCC and thyroid cancer are the classic causes of hypervascular, hemorrhage-prone bone metastases.
• The commonest distractor: choosing cytotoxic chemotherapy or conventional radiotherapy — RCC is resistant to both. Systemic therapy is checkpoint inhibitor–based combinations or VEGF/HIF-2α–targeted agents.
• Do not conflate: the classic triad of flank pain, hematuria, and palpable mass appears in under 10%; most tumors today are incidental CT findings.